Adi Kartolo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adi Kartolo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Yeung
Kingston Health Sciences Centre, Kingston, Ontario, Canada
2 shared publications - Tara Baetz
Department of Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, 25 King Street West, Kingston, Ontario, K7L 5P9, Canada
2 shared publications Wilma Hopman
Kingston Health Sciences Centre, Kingston, Ontario, Canada
2 shared publicationsCheng S
1 shared publication- Francisco Emilio Vera Badillo
13Kingston Health Sciences Centre, Kingston, Ontario, Canada
1 shared publication Gordon T Moffat
Cancer Care of Southeastern Ontario, Kingston, Ontario, Canada
1 shared publication
Latest Publications
- 16 May 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (11) , 819-826
Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma
Aims: Chronomodulation of immune checkpoint inhibitors (ICIs) is not well understood. The authors evaluated the circadian timing of initial ICI infusions. Patients & methods: A retrospective cohort... Tweetable abstract Later time of day of the first several infusions of immune checkpoint inhibitors was associated with worse overall survival in patients with advanced melanoma.
- 16 May 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (11) , 819-826
Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma
Aims: Chronomodulation of immune checkpoint inhibitors (ICIs) is not well understood. The authors evaluated the circadian timing of initial ICI infusions. Patients & methods: A retrospective cohort... Tweetable abstract Later time of day of the first several infusions of immune checkpoint inhibitors was associated with worse overall survival in patients with advanced melanoma.
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (31) , 3573-3575
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
Triplet therapy may be a viable but should not be the default option for all men with mHSPC
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (31) , 3573-3575
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
Triplet therapy may be a viable but should not be the default option for all men with mHSPC
- 11 November 2021
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (1) , 23-30
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors
Aim: To evaluate the correlation between venous thromboembolism events (VTEs) and immune checkpoint inhibitor (ICI)-based regimens. Methods: This is a retrospective study of 403 patients with advan...
- 11 November 2021
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (1) , 23-30
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors
Aim: To evaluate the correlation between venous thromboembolism events (VTEs) and immune checkpoint inhibitor (ICI)-based regimens. Methods: This is a retrospective study of 403 patients with advan...
- 28 January 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (1) , 87-95
Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer
Aim: To evaluate the impact of discrepancy between prescribed and recommended fixed 200 mg dose (P-F discrepancy) on immune-related adverse events (irAEs) and treatment efficacy in patients with advanced melanoma and NSCLC. Methods: This retrospective study included 177 patients with advanced melanoma or non-small cell lung cancer (NSCLC) who received at least one cycle of single-agent pembrolizumab. We defined P-F discrepancy as the differences between prescribed pembrolizumab dose and 200 mg recommended dose, expressed in percentages. Our primary outcome was immune-related adverse events (irAEs), and our secondary outcomes included overall survival (OS) and progression free survival (PFS). Results: The median P-F discrepancy was –21.5%, with the 25th and 75th percentile at –32% and –5.0% respectively. ROC curve analyses did not show any optimal cutoffs to prognosticate irAEs (AUC = 0.558 for all patients) or cancer mortality (AUC = 0.583 for melanoma; AUC = 0.539 for NSCLC) in either cancer type. Separate multivariable Cox analyses suggested no statistically significant association between P-F discrepancy and overall survival in patients with melanoma (HR 1.012, 95%CI 0.987–1.038, P = 0.362) or NSCLC (HR 0.998, 95%CI 0.978–1.019, P = 0.876). Conclusion: There was no optimal pembrolizumab cut-off point to predict irAEs or treatment efficacy. We supported the use of weight-based pembrolizumab dosing, given the potential cost-saving and no differences in terms of irAEs or treatment efficacy in patients with advanced melanoma or NSCLC. Future studies on province- or national-level would be important to validate our findings.
- 28 January 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (1) , 87-95
Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer
Aim: To evaluate the impact of discrepancy between prescribed and recommended fixed 200 mg dose (P-F discrepancy) on immune-related adverse events (irAEs) and treatment efficacy in patients with advanced melanoma and NSCLC. Methods: This retrospective study included 177 patients with advanced melanoma or non-small cell lung cancer (NSCLC) who received at least one cycle of single-agent pembrolizumab. We defined P-F discrepancy as the differences between prescribed pembrolizumab dose and 200 mg recommended dose, expressed in percentages. Our primary outcome was immune-related adverse events (irAEs), and our secondary outcomes included overall survival (OS) and progression free survival (PFS). Results: The median P-F discrepancy was –21.5%, with the 25th and 75th percentile at –32% and –5.0% respectively. ROC curve analyses did not show any optimal cutoffs to prognosticate irAEs (AUC = 0.558 for all patients) or cancer mortality (AUC = 0.583 for melanoma; AUC = 0.539 for NSCLC) in either cancer type. Separate multivariable Cox analyses suggested no statistically significant association between P-F discrepancy and overall survival in patients with melanoma (HR 1.012, 95%CI 0.987–1.038, P = 0.362) or NSCLC (HR 0.998, 95%CI 0.978–1.019, P = 0.876). Conclusion: There was no optimal pembrolizumab cut-off point to predict irAEs or treatment efficacy. We supported the use of weight-based pembrolizumab dosing, given the potential cost-saving and no differences in terms of irAEs or treatment efficacy in patients with advanced melanoma or NSCLC. Future studies on province- or national-level would be important to validate our findings.
- Open Access
- 3 March 2017
- Published by SciDoc Publishers LLC in International Journal of Cancer Studies & Research
- p. 115-121
Frequency and Determining Factors of Empiric Chemotherapy Dose Reduction in Patients with Non-Small Cell Lung Cancer
- 3 March 2017
- Published by SciDoc Publishers LLC in International Journal of Cancer Studies & Research
- p. 115-121
Open AccessFrequency and Determining Factors of Empiric Chemotherapy Dose Reduction in Patients with Non-Small Cell Lung Cancer